Prognostic Biomarkers Market Set for Rapid Growth And Trend, by 2027
Novel drug efficiency in clinical trials on a certain population is determined using prognostic biomarkers. Hence, prognostic biomarkers have remarkable potential to affect the success rate of clinical trials. They also help in assessing the need and strategy of treatment for specific patients. In the era of personalized medicines and advanced cancer therapeutics, prognostic markers provide the precise selection of treatment for a patient. Thus, helps in reducing the side effects of chemotherapeutic drugs. For the further prediction and development of novel prognostic biomarkers, collaboration of statistical and bioinformatics data is also required.
Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-3139
Prognostic Biomarkers Market: Drivers & Restraints
An ideal biomarker should have analytical validity, clinical validity and clinical utility. Hence, fast, accurate and feasible prognostic biomarker will grow the demand of industry. Also, not all the patients respond favorably to drugs so continuous need of prognostic biomarkers is there for regular assessment of the treatment. Furthermore, increased development of prognostic biomarkers will reduce the treatment cost. Increasing awareness among doctors, patients and technicians in the developing countries would help in promoting the growth of market. Insufficient partnership between industry and academia is one of the restraint of the industry. More chances of experimental failure, some ethical issues, huge investment, time consumption, technical and commercial challenges limits further development of prognostic biomarkers.
Prognostic Biomarkers Market: Segmentation
Segmentation by Therapeutic Type
Diabetes and others
Segmentation by End User
Segmentation by Application
Drug discovery and research
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-3139
Prognostic Biomarkers Market: Overview
Currently, clinicians monitor treatment response by means of blood pressure measurements, anti-double-stranded DNA antibody levels, serum complement levels, urinary protein/creatinine ratios, urinary sediment, and surrogates of renal function. Unfortunately, prediction of disease progression is difficult by using these traditional biomarkers because of their little sensitivity and high LN heterogeneity at presentation. Therefore, continuous need of prognostic biomarker increases for effective treatment strategy these days. Prognostic biomarkers also help the pharmaceutical industry to develop more effective drug and reduce the chances of failure. Sensitivity, specificity and cost are some of the factors determining growth of the industry. The market demand of prognostic biomarkers will increase because of the factors like increasing population, increase in number of chronic diseases, increased investment in healthcare and many more.
Long term investments is one of the requirement essential for the novel systems and thus promoting growth of the industry. One of the commercialized prognostic biomarker assay kit is the Oncotype DX which determine the likelihood that breast cancer will come back in a patient after initial treatment. Similar research activity include Komen funded research projects on prognostic biomarkers which have investment of around $ 60 million in over 120 research grants.
Prognostic Biomarkers Market: Region-wise Outlook
North America dominates the global market because of increasing aging population and increasing innovation and technology. According to WHO cancer trends worldwide, North America is at the top followed by Europe. Furthermore, good reimbursement scenario in these countries increase the demand. Asia-pacific region market is expected to grow in the future because of increase in the number of contract research, increasing population and per capita income of people in these countries. Development of novel biomarkers and their increasing use also help in cutting down the healthcare cost thus promoting the growth of the industry.
Prognostic Biomarkers Market: Key Players
Some of the key players in the prognostic biomarkers industry include Roche diagnostics, Qiagen, Johnson and Johnson, GE Healthcare, Siemens Healthcare, Merck & Co. Inc. and many others.
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Prognostic Biomarkers Market Set for Rapid Growth And Trend, by 2027 here
News-ID: 486235 • Views: 216
More Releases from Future Market Insights
The German Tortilla Mix Market is estimated to grow at a CAGR of 4.7% by 2023 to …
In 2023, the market share of tortilla mix was estimated to be worth US$ 12.23 billion. By 2033, it was estimated to be worth US$ 23.18 billion. This is expected to further boost the market share of the tortilla mix and generate a CAGR of 6.6%. The nutritional benefits of tortillas have become increasingly popular in both developed and developing countries. At the same time, a growing number of people are
Asian pacific Sheep Shearing Equipment Market was valued at US$ 91.4 Million by …
The global sheep shearing equipment market was valued at US$ 755.8 Mn in 2022. The market is expected to develop from US$ 780 Mn in 2023 to US$ 1,069 Mn by 2033, registering a CAGR of 3.2% over the forecast period. Shearing machinery is used on farms to cut or remove wool from sheep's bodies. The exceptional qualities of this equipment have increased demand. The need for sheep shearing equipment is growing since regular shearing is necessary to keep
The UK Stock Tank Market was valued at US$ 499.2 Million by the time of 2033
A CAGR of 6.5% is predicted for the global stock tank market over the forecast period. The market is anticipated to increase from US$ 2.82 Bn in 2023 to US$ 5.30 Bn by 2033. The stock tank business has recently seen tremendous demand. The summer has grown more challenging for both humans and animals due to global warming. To save the farm animals and combat the heat, farms are installing stock tank pools significantly. Increasing demands for increased
By 2032, the Egg Albumin Protein Market is expected to be worth US$ 2.88 Billion
According to a recent report published by Future Market Insights, sales of egg albumin protein are estimated to reach a valuation of US$ 2.88 Bn by 2032, surging at 7.3% CAGR during the forecast period of 2022 to 2032. Egg albumin protein is absorbed by the blood and is used to separate proteins. It is expected to gain high popularity across the globe, especially in the sports nutrition sector owing to its ability
More Releases for Prognostic
Know How Prognostic Biomarkers Market is rising globally by 2027
Prognostic Biomarkers Market Study 2022-2027: Prognostic Biomarkers Market (Newly published report) which covers Market Overview, Future Economic Impact, Competition by Manufacturers, Supply (Production), and Consumption Analysis, and focuses on various products and other market trends. The market research report on the global Prognostic Biomarkers industry provides a comprehensive study of the various techniques and materials used in the production of Prognostic Biomarkers market products. Starting from industry chain analysis to cost structure
Prognostic Biomarkers Market Analysis and Opportunity Assessment 2017-2027
"The Latest Research Report Prognostic Biomarkers Market: Global Industry Analysis and Opportunity Assessment 2017-2027 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Prognostic Biomarkers are the type of biomarkers that track the progression of a disease with or without treatment. They assess the aggressiveness of the disease and calculate the risk of recurrence or median survival for particular type of malignancy. According
Commercial vehicle prognostic system Market Greater Revenue Share by 2017 - 2025
Commercial vehicle prognostic systems are used to calculate the failure time for various systems and their components. Here, failure signifies the point at which a system can no longer be used to deliver the desired task or performance. Moreover, commercial vehicle prognostic has been a new area of development in telematics over the years. Commercial vehicle prognostic systems are capable of communicating the cause problem of any vehicle system and
Commercial Vehicle Prognostic System Market Trends and Segments 2017-2025
Introduction: Commercial vehicle prognostic systems are used to calculate the failure time for various systems and their components. Here, failure signifies the point at which a system can no longer be used to deliver the desired task or performance. Moreover, commercial vehicle prognostic has been a new area of development in telematics over the years. Commercial vehicle prognostic systems are capable of communicating the cause problem of any vehicle system and
Global Circulating Tumor Cells Prognostic Technologies Market $2.3 Billion by 20 …
Circulating Tumor Cells Prognostic Technologies Market Analysis and Forecast 2017-2021 report estimates the global circulating tumor cells prognostic technologies market to reach nearly $2.3 Billion in 2021, at a CAGR of 18.5% from 2017 to 2021 - iHealthcareAnalyst, Inc. There is a great potential of Circulating tumor cells (CTCs) to be used as pharmacodynamic and predictive biomarkers and potentially their use in revealing drug resistance in real time. CTCs are cells
Prognostic Biomarkers Market Industry Analysis, Trend and Growth, 2017-2027
Prognostic Biomarkers are the type of biomarkers that track the progression of a disease with or without treatment. They assess the aggressiveness of the disease and calculate the risk of recurrence or median survival for particular type of malignancy. According to an article published in Journal of Clinical and Cellular Immunology, the field of biomarkers has expanded dramatically in the last 5-6 years with the advancement in high throughput technologies